935758-15-9 Usage
Uses
Used in Organic Synthesis:
3-OXO-3,4-DIHYDRO-2H-BENZO[B][1,4]OXAZINE-8-CARBALDEHYDE is used as a key building block in organic synthesis for its ability to contribute to the formation of complex molecular structures. Its unique ring system and functional groups make it a versatile component in creating a wide array of organic compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-OXO-3,4-DIHYDRO-2H-BENZO[B][1,4]OXAZINE-8-CARBALDEHYDE is utilized as a precursor or intermediate in the development of pharmaceuticals. Its potential biological activities and chemical reactivity allow it to be a part of the molecular scaffolds for new drug discoveries.
Used in Pharmaceutical Industry:
3-OXO-3,4-DIHYDRO-2H-BENZO[B][1,4]OXAZINE-8-CARBALDEHYDE is used as a starting material for the synthesis of various pharmaceutical agents. Its specific properties can be harnessed to target and treat a range of medical conditions, making it an important compound in drug design and development.
Used in Chemical Research:
3-OXO-3,4-DIHYDRO-2H-BENZO[B][1,4]OXAZINE-8-CARBALDEHYDE also serves as a subject of interest in chemical research, where its reactivity, stability, and the possibility of forming new derivatives are explored. Researchers use it to study reaction mechanisms, develop new synthetic routes, and understand its potential applications in material science and other related fields.
Check Digit Verification of cas no
The CAS Registry Mumber 935758-15-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,5,7,5 and 8 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 935758-15:
(8*9)+(7*3)+(6*5)+(5*7)+(4*5)+(3*8)+(2*1)+(1*5)=209
209 % 10 = 9
So 935758-15-9 is a valid CAS Registry Number.
935758-15-9Relevant academic research and scientific papers
Giubellina, Nicola,Stabile, Paolo,Laval, Gilles,Perboni, Alcide D.,Cimarosti, Zadeo,Westerduin, Pieter,Cooke, Jason W. B.
, p. 859 - 867 (2010)
The development and scale-up of an optimized synthesis for a novel drug candidate for depression and anxiety is presented. The updated synthesis represents a convergent and efficient four-stage approach to the API, overcoming high cost of goods (COG), gen
